LIVE April 19th, 2022 at 11:30 AM Biologics targeting coronavirus and variants of interest emerge as the latest therapeutic strategy for treating COVID-19.
A naturally occurring nanoparticle yields a new type of vaccine that offers broad-acting protection against emerging SARS-CoV-2 variants. With further development, the approach may lead to a pan-coronavirus vaccine.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.